Exendin-4
Exendin-4 (Exenatide precursor)
A GLP-1 receptor agonist originally isolated from Gila monster saliva. The basis for Exenatide (Byetta/Bydureon), one of the first GLP-1 agonists approved for diabetes.
Mechanism of Action
Exendin-4 binds to GLP-1 receptors with high affinity and a longer half-life than native GLP-1. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.
Health Claims & Evidence
Improves glycemic control in type 2 diabetes
Promotes weight loss
Neuroprotective effects
Short-Term Effects
Improved glycemic control, nausea (especially initially), weight loss.
Long-Term Effects
Sustained glycemic control and weight loss.
Side Effects
Nausea, vomiting, diarrhea. Rare: pancreatitis.
Contraindications
Avoid with personal/family history of medullary thyroid carcinoma.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Exenatide in type 2 diabetes
Buse et al. · Diabetes Care · 2004
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Exendin-4 and related peptides, and prepare an educational research summary.
Explore Research